Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis

Blood Advances
R M StoneRenaud Capdeville

Abstract

Midostaurin was a prototype kinase inhibitor, originally developed as a protein kinase C inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor. Despite promising preclinical data, early clinical trials in multiple diseases showed only modest efficacy. In 1996, the relatively frequent occurrence of fms-like tyrosine kinase 3 (FLT3) activating mutations in acute myeloid leukemia (AML) was first recognized. Several years later, midostaurin was discovered to be a potent inhibitor of the FLT3 tyrosine kinase and to have activity against mutant forms of KIT proto-oncogene receptor tyrosine kinase, which drive advanced systemic mastocytosis (SM). Through a series of collaborations between industry and academia, midostaurin in combination with standard chemotherapy was evaluated in the Cancer and Leukemia Group B 10603/RATIFY study, a large, phase 3, randomized, placebo-controlled trial in patients with newly diagnosed FLT3-mutated AML. This was the first study to show significant improvements in overall survival and event-free survival with the addition of a targeted therapy to standard chemotherapy in this population. Around the same time, durable responses wer...Continue Reading

References

Jan 1, 1991·Advances in Pharmacology·J E Casnellie
May 20, 1990·Journal of Molecular Biology·C W BoysP G Stockley
Jun 1, 1989·Trends in Pharmacological Sciences·U T Rüegg, G M Burgess
Mar 13, 1986·Biochemical and Biophysical Research Communications·T TamaokiF Tomita
Jan 25, 2000·American Journal of Physiology. Cell Physiology·H NagumoY Takuwa
May 9, 2000·Critical Reviews in Oncology/hematology·A Gescher
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D J PropperC Twelves
Jul 4, 2001·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·K NakamuraH Kanaide
Jan 5, 2002·Expert Opinion on Investigational Drugs·P G Goekjian, M R Jirousek
Jul 12, 2002·The Hematology Journal : the Official Journal of the European Haematology Association·Andres VirchisAtul Mehta
Jul 18, 2002·Nature Reviews. Drug Discovery·Renaud CapdevilleAlex Matter
May 14, 2003·Transplantation Proceedings·S N Sehgal
Feb 27, 2004·Investigative Ophthalmology & Visual Science·Peter A Campochiaro, UNKNOWN C99-PKC412-003 Study Group
Dec 15, 2007·Genes & Development·Sreenath V Sharma, Jeffrey Settleman
Jan 10, 2008·Nature Biotechnology·Mazen W KaramanPatrick P Zarrinkar
May 3, 2008·Leukemia & Lymphoma·Keith Pratz, Mark Levis
May 14, 2008·Current Medicinal Chemistry·Michael Fährmann
May 30, 2008·Journal of Clinical Pharmacology·Yanfeng WangHorst Schran
Sep 2, 2008·Seminars in Hematology·Donald Small
Apr 8, 2010·Current Drug Targets·Keith W Pratz, Mark J Levis
Dec 1, 2012·Nature Reviews. Drug Discovery·Daria Mochly-RosenKevin V Grimes
Jun 30, 2016·The New England Journal of Medicine·Jason GotlibAndreas Reiter
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner

❮ Previous
Next ❯

Citations

Jan 15, 2019·Current Opinion in Hematology·Luke Fletcher, Uma Borate
Mar 13, 2019·Genes, Chromosomes & Cancer·Ing S Tiong, Andrew H Wei
Dec 7, 2018·Hematology·Rachel E Rau, Mignon L Loh
Jul 23, 2019·Journal of Enzyme Inhibition and Medicinal Chemistry·Samar IssaZouhair Bouaziz
May 24, 2019·British Journal of Haematology·Frederick FasslrinnerMichael Bachmann
Jan 17, 2020·Expert Review of Proteomics·Anneke D van DijkSteven M Kornblau
Jan 24, 2020·Annals of Hematology·Saša Anžej DomaMatjaž Sever
Dec 27, 2019·American Journal of Clinical Oncology·Steven Lehrer, Peter H Rheinstein
Jan 12, 2020·Cancer Metastasis Reviews·Shannon E Conneely, Rachel E Rau
Sep 19, 2019·Biomarker Research·Juanjuan ZhaoDelong Liu
Dec 6, 2018·Journal of Hematology & Oncology·Mei WuXiongpeng Zhu
Jan 30, 2019·Current Opinion in Hematology·Luke Fletcher, Uma Borate
Jul 25, 2019·International Journal of Molecular Sciences·Solène FernandezPierre-Yves Dumas
Jul 24, 2020·Oncology and Therapy·Alessandro FiorentiniAttilio Olivieri
Jan 31, 2019·International Journal of Molecular Sciences·Noelia Dasilva-FreireAlberto Orfao
Jan 24, 2020·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Gabriel TremblayAnna Forsythe
Jun 2, 2020·Biomarker Research·Jifeng YuYongping Song
Dec 14, 2018·International Journal of Molecular Sciences·Iris Z UrasVeronika Sexl
Feb 12, 2020·Seminars in Cancer Biology·Vinayak PalveUwe Rix
Jan 23, 2021·Journal of Medicinal Chemistry·Zhouling XieChenzhong Liao
Nov 21, 2020·Journal of Hematology & Oncology·Melat T Gebru, Hong-Gang Wang
Jan 7, 2021·Cancers·Luca MologniAlfonso Zambon
Feb 18, 2021·Expert Review of Hematology·Tara L Lin, Livio Pagano
Mar 13, 2020·Journal of Natural Products·David J Newman, Gordon M Cragg
Mar 27, 2019·Current Opinion in Chemical Biology·Marcus Jc LongYimon Aye
Apr 4, 2021·Pharmacology & Therapeutics·Mohammed F AlmataniHouda Alachkar
Apr 13, 2021·Frontiers in Oncology·Kristine Yttersian SlettaBjørn Tore Gjertsen
Apr 16, 2021·Expert Opinion on Drug Safety·Giovanni MarconiGiovanni Martinelli
Apr 28, 2021·European Journal of Medicinal Chemistry·Xiaoxia LiangBo Jing

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.